Sanofi ADR (SNY)

The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers

Zacks Investment Research

Could Novavax Become the Next Moderna?

The Motley Fool

Top Analyst Reports for Oracle, Bank of America & McDonald's

Zacks Investment Research

Quarterly Snapshot: Quick and Current Ratios for Sanofi ADR (SNY) – DWinneX - The Dwinnex

The Dwinnex

Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY

Zacks Investment Research

SNY’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

The InvestChronicle

Pfizer: Best Trading Momentum Since 2021 And 6% Yield

Seeking Alpha

2024-05-15 | NYSE:TEVA | Press Release | Teva Pharmaceutical Industries ADR Representing One - Stockhouse Publishing

Stockhouse Publishing

Sanofi ADR: Is SNY Stock Worth Buying? – Stocks Register - Stocks Register

Stocks Register

Novavax Stock Just Tripled. Is It Too Late to Buy?

The Motley Fool

Novavax (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal

Zacks Investment Research

Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag

Zacks Investment Research

Company News For May 13, 2024

Zacks Investment Research

Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday? (CORRECTED)

Benzinga

Why Novavax Stock More Than Doubled Today

The Motley Fool

Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday?

Benzinga

Novavax shares skyrocket after billion-dollar licensing deal with Sanofi - Proactive Investors UK

Proactive Investors UK

Novavax shares soar on license deal with Sanofi at lofty valuation - The Globe and Mail

The Globe and Mail

Novavax's share price surges after inking co-licensing deal with pharma giant - The Business Journals

The Business Journals

Novavax shares soar on license deal with Sanofi at lofty valuation - The Globe and Mail

The Globe and Mail

Sanofi's New Cancer Drug Could Help Deliver a Big Payday

The Motley Fool

Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus

Zacks Investment Research

Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus

Zacks Investment Research

Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales

Zacks Investment Research

3 Biotech Stocks to Buy and Hold Through 2030 and Beyond

The Motley Fool

Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?

Zacks Investment Research

Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates

Zacks Investment Research

AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up

Zacks Investment Research

Sanofi (SNY) Q1 2024 Earnings Call Transcript

The Motley Fool

Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up

Zacks Investment Research

US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst

Benzinga

What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?

Zacks Investment Research

Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study

Zacks Investment Research

AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect

Zacks Investment Research

10 Best Blue-Chip Stocks to Buy for the Long Term - Morningstar

Morningstar

Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week

Benzinga

Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick

Benzinga

International Wide-Moat Stocks On Sale - The April 2024 Heat Map

Seeking Alpha

Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says

Benzinga

Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study

Zacks Investment Research

Pfizer's (PFE) RSV Vaccine Study in Adults Under 60 Meets Goal

Zacks Investment Research

Sanofi: My Top Pick In Big Pharma

Seeking Alpha

SNY: Top 3 Pharma Innovators to Watch Closely - StockNews.com

StockNews.com

Regeneron (REGN) Gets FDA Nod for Praluent Label Extension

Zacks Investment Research

ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study

Zacks Investment Research

J&J (JNJ) Seeks Expanded Use of Tremfya for Ulcerative Colitis

Zacks Investment Research

Weekly Upgrades and Downgrades - InvestorPlace

InvestorPlace

Local CF startup raises one of the largest VC rounds in Mass. so far this year - Boston Business Journal - Boston Business Journal

Boston Business Journal

Beyond the Magnificent 7, These European Giants Keep Soaring Under the Radar

Investing.com

‘GRANOLAS’ vs. the Magnificent Seven: Which should you dig into now?

MarketWatch